CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), announces it has entered into a definitive asset purchase agreement to acquire the business of DOASENSE GmbH, Heidelberg, a pioneer in specialized diagnostic solutions for Direct Oral Anticoagulants (DOACs). This strategic acquisition is designed to expand CoaguSense’s portfolio beyond traditional Vitamin K Antagonist (VKA) monitoring to include rapid, point-of-care testing for the dynamically growing DOAC market.
Read the full article: CoaguSense Announces Agreement to Acquire DOASENSE DOAC Testing Business, Expanding Leadership in Anticoagulation Monitoring //
Source: https://www.globenewswire.com/news-release/2026/03/23/3260114/0/en/CoaguSense-Announces-Agreement-to-Acquire-DOASENSE-DOAC-Testing-Business-Expanding-Leadership-in-Anticoagulation-Monitoring.html?_gl=1*rl9ex4*_up*MQ..*_ga*MTQzODgzNDMzNi4xNzc0MjQ4NDY2*_ga_B6167QB2TF*czE3NzQyNDg0NjUkbzEkZzAkdDE3NzQyNDg0NjUkajYwJGwwJGgw*_ga_ERWPGTJ5X8*czE3NzQyNDg0NjUkbzEkZzAkdDE3NzQyNDg0NjUkajYwJGwwJGgw